Skip to main content
tarnok ferenc - nyelocso gastroenterologia


1. Kang JY.: Systematic review: Geographical and ethnic differences in gastrooesophageal
reflux disease. Aliment. Pharm. Ther. 2004; 20/7:705-17.
2. Goh KL.: Changing epidemiology of gastroesophageal reflux disease in the AsianPacific
Pacific region: An overview. J. Gastroenterol. Hepatol. 2004; 19/3.
3. ElSerag HB., Petersen NJ., Carter J., Graham DY., Richardson P., Genta RM.,
Rabeneck L.: Gastroesophageal reflux among different racial groups in the United
States. Gastroenterology 2004; 126/7:1692-99.
4. Penagini R., Allocca M., Cantu P., Mangano M., Savojardo D., Carmagnola S.,
Bianchi PA.: Relationship between motor function of the proximal stomach and
transient lower oesophageal sphincter relaxation after morphine. Gut 2004; 53/9:
5. Penagini R., Carmagnola S., Cantu P., Allocca M., Bianchi PA.: Mechanoreceptors
of the proximal stomach: Role in triggering transient lower esophageal sphincter
relaxation. Gastroenterology 2004; 126/1:49-56.
6. Kulig M., Nocon M., Vieth A., Leodolter A., Jaspersen D., Labenz J.,
MeyerSabellek W., Stolte M., Lind T., Malfertheiner P., Willich SN.: Risk factors
of gastroesophageal reflux disease: methodology and first epidemiological results of
the ProGERD study. J. Clin. Epidemiol. 2004; 57/6:580-89.
7. Nilsson M., Johnsen R., Ye W., Hveem K., Lagergren J.: Lifestyle related risk in
the aetiology of gastro-oesophageal reflux. Gut 2004; 53/12:1730-35.
8. ElSerag HB., Satia JA., Rabeneck L.: Dietary intake and risk of gastro-oesophageal
reflux disease: a cross sectional study in volunteers. Gut 2004; 54/1:11-17.
9. ElSerag HB., Gilger M., Carter J., Genta RM., Rabeneck L.: Childhood GERD is
a risk factor for GERD in adolescents and young adults. Am. J. Gastroenterol. 2004;
10. Pace F., Porro GB.: Gastroesophageal reflux disease: A typical spectrum disease (A
new conceptual framework is not needed). Am. J. Gastroenterol. 2004; 99/5:946-49.

11. Labenz J., Jaspersen D., Kulig M., Leodolter A., Lind T., MeyerSabellek W.,
Stolte M., Vieth M., Willich S., Malfertheiner P.: Risk factors for erosive
esophagitis: A multivariate analysis based on the ProGERD study initiative. Am.
J. Gastroenterol. 2004; 99/9:1652-56.
12. Martinek J., Benes M., Hucl T. et al.: How do endoscopy positive and endoscopy
negative gastroesophageal reflux diseases differ? Prospective evaluation of patients
with gastroesophageal reflux disease (GERD) /Abstract/ Gastroenterology 2004;
13. Gordon C., Kang JY., Neild PJ., Maxwell JD.: Review article: The role of the hiatus
hernia in gastro-oesophageal reflux disease. Aliment. Pharm. Ther. 2004; 20/7:719-
14. Lin M., Gerson LB., Lascar R., Davila M., Triadafilopoulos G.: Features of
gastroesophageal reflux disease in women. Am. J. Gastroenterol.: 2004; 99/8:1442-
15. Miwa H., Minoo T., Hojo M., Yaginuma R., Nagahara A., Kawabe M., Ohkawa
A., Asaoka D., Kurosawa A., Ohkusa T., Sato N.: Oesophageal hypersensitivity in
Japanese patients with non-erosive gastro-oesophageal reflux diseases. Aliment.
Pharmacol. Ther. 2004; 20/Suppl 1:112-17.
16. Fletcher J., Wirz A., Henry E., McColl KEL.: Studies of acid exposure immediately
above the gastro-oesophageal squamocolumnar junction: Evidence of short segment
reflux. Gut 2004; 53/2:168-173.
17. Peitz U., Kouznetsova I., Wex T., Gebert I., Vieth M., Roesner A., Hoffmann W.,
Malfertheiner P.: TFF3 expression at the esophagogastric junction is increased in
gastro-esophageal reflux disease (GERD). Peptides 2004; 25/5:771-77.
18. Isomoto H., Saenko VA., Kanazawa Y., Nishi Y., Ohtsuru A., Inoue K., Akazawa
Y., Takeshima F., Omagari K., Miyazaki M., Mizuta I., Murata I., Yamashita S.,
Kohno S.: Enhanced expression of interleukin-8 and activation of nuclear factor
kappa B in endoscopy-negative gastroesophageal reflux disease. Am. J.
Gastroenterol. 2004; 99/4:589-597.
19. Jenkins GJS., Harries K., Doak SH., Wilmes A., Griffiths AP., Baxter JN., Parry
JM.: The bile acid deoxycholic acid (DCA) at neutral pH activates NF-kappa B and
induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis 2004; 25/3:317-
20. Hamoui N., Peters JH., Schneider S., Uchida K., Yang DY., Valboehmer D.,
Hagen JA., DeMeester SR., DeMeester TR., Danenberg K., Danenberg P.:
Increased acid exposure in patients with gastroesophageal reflux disease influences
cyclooxygenase-2 gene expression in squamous epithelium of the lower esophagus.
Arch. Surg. 2004; 139/7:712-717.
21. Sontag SJ., O’Connell S, Miller TQ., Bernsen M., Seidel J.: Asthmatics have more
nocturnal gasping and reflux symptoms than nonasthmatics, and they are related to
bedtime eating. Am. J. Gastroenterol. 2004; 99:789-96.
22. Öztürk Ö., Öztürk L., Özdogan A., Öktem F., Pelin Z.: Variables affecting the
occurrence of gastroesophageal reflux in obstructive sleep apnea patients. Eur. Arch.
Oto-Rhino-Laryngology 2004; 261/4.229-32.
23. Berg S., Hoffstein V., Gislason T.: Acidification of distal esophagus and sleep-related
breathing disturbances. Chest 2004; 125/6:2101-2106.
24. Koek GH., Vos R., Flamen P., Sifrim D., Lammert F., Vanbilloen B., Janssens J.,
Tack J.: Oesophageal clearance of acid and bile: a combined radionuclide, pH, and
Bilitec study. Gut 2004; 53/1:21-26.
25. Johnson DA., Fennerty MB.: Heartburn severity underestimates erosive esophagitis
severity in elderly patients with gastroesophageal reflux disease. Gastroenterology
2004; 126/3:660-64.
26. Dent J., Armstrong D., Delaney B., Moayyedi P., Talley NJ., Vakil N.: Symptom
evaluation in reflux disease: workshop background, processes, terminology,
recommendations, and discussion outputs. Gut 2004; 53/4 Suppl.:1-24.
27. Fock KM., Talley N., Hunt R., Fass R., Nardurkar S., Lam SK., Goh KL, Sollano
J.: Report of the Asia-Pacific consensus on the management of gastroesophageal
reflux disease. J. Gastroenterol. Hepatol. 2004; 19/4:357-67.
28. Numans ME., Lau J., de Wit NJ., Bonis PA.: Short-term treatment with protonpump
inhibitors as a test for gastro-esophageal reflux disease: A meta-analysis of
diagnostic test characteristics. Ann. Intern. Med. 2004; 140:518-27.
29. Williams RBH., Szczesniak MM., Maclean JC., Brake HM., Cole IE., Cook IJ.:
Predictors of outcome in an open label, therapeutic trial of high-dose omeprazole in
laryngitis. Am. J. Gastroenterol. 2004; 99:777-85.
30. Tack J., Koek G., Dements I., Sifrim D., Janssens J.: Gastroesophageal reflux
disease poorly responsive to single-dose proton pump inhibitors in patients without
Barrett’s esophagus: Acid reflux, bile reflux, or both? Am. J. Gastroenterol. 2004;
31. Shay S., Tutuian R., Sirfim D., Vela M., Wise J., Balaji N., Zhang X., Adhami T.,
Murray J., Peters J., Castell D.: Twenty-four hour ambulatory simultaneous
impedance and pH monitoring: A multicenter report of normal values from 60 healthy
volunteers. Am. J. Gastroenterol. 2004; 99/6:1037-43.
32. Balaji NS., Blom D., DeMeester, Peters JH.: Redefining gastroesophageal reflux
(GER) – Detection using multichannel intraluminal impedance in healthy volunteers.
Surg. Endoscopy Interv.Techn. 2004; 17/9:1380-85.
33. Sirfim D.,Castell D., Dent J., Kahrilas PJ.: Gastro-oesophageal reflux monitoring:
review and consensus report on detection and definitions of acid, non-acid, and gas
reflux. Gut 2004; 53/7:1024-31.
34. Tutuian R. and Castell DO.: Clarification of the esophageal function defect in
patients with manometric ineffective esophageal motility: Studies using combined
impedance-manometry. Clin. Gastroenterol. Hepatol. 2004; 2:230-36.
35. Tu CH., Lee YC., Wang HP., Wu MS., Chiu HM., Lin JT.: Ambulatory esophageal
pH monitoring by using a wireless system: A pilot study in Taiwan. HepatoGastroenterol.
2004; 51/60:1586-89.
36. Tamhankar AP., Peters JH., Portale G., Hsieh CC., Hagen JA., Bremner CG.,
DeMeester TR.: Omeprazole does not reduce gastroesophageal reflux: New insights
using multichannel intraluminal impedance technology. J. Gastroint. Surgery 2004;
37. Yeh RW., Gerson LB., Triadafilopoulos G.: Efficacy of esomeprazole in controlling
reflux symptoms, intraesophageal and intragastric pH in patients with Barrett’s
esophagus. Dis. Esophagus 2003; 16/3:193-98.
38. Milkes D., Gerson LB., Triadafilopoulos G.: Complete elimination of reflux
symptoms does not guarantee normalization of intraesophageal and intragastric pH in
patients with gastroesophageal reflux disease (GERD). Am. J. Gastroentereol. 2004;
39. Achem SR.: Acid inhibition in GERD – How much is enogh? Am. J. Gastroenterol.
2004; 99/6:997-99.
40. Corley DA., Katz P., Wo JM., Stefan A., Patti M., Rothstein R., Edmundowicz S.,
Kline M., Mason R., Wolfe MM.: Improvement of gastro-esophageal reflux
symptoms after radiofrequency energy: A randomized, sham-controlled trial.
Gastroenterology 2003; 125:668-76.
41. Talley NJ.: What the physician needs to know for correct management of gastrooesophageal
reflux disease and dyspepsia. Aliment. Pharmacol. Ther. 2004; 20/2
Suppl. 23-30.
42. Jonaitis LV., Kiudelis G., Kupcinskas L.: Characteristics of patients with erosive
and nonerosive GERD in high-Helicobacter-pylori prevelence region. Dis. Esophagus
2004; 17/3:223-27.
43. Wu JCY, Chan FKL., Ching JYL., Leung WK., Hui Y., Leong R., Chung SCS,
Sung JJY.: Effect of Helicobacter pylori eradication on treatment of gastrooesophageal
reflux disease. A double blind, placebo controlled, randomized trial. Gut
2004; 75/2:l74-l79.
44. Peitz U., Raps S., Plein K., Leodolter A., Hotz J., Malfertheiner P.: Long-term
course of reflux symptoms following Helicobacter pylori eradication. Dtsch. Med.
Wschr. 2004; 129/13:671-75.
45. Harvey RF., Lane JA., Murray LJ., Harvey IM., Donovan JL., Nair P.:
Randomized controlled trial of effects of Helicobacter pylori infection and its
eradication on heartburn and gastro-oesophageal reflux: Bristol helicobacter project.
Br. Med. J. 2004; 328/7453: 1417-19.
46. Richter JE.: Effect of Helicobacter pylori eradication on the treatment of gastrooesophageal
reflux disease. Gut 2004; 53/2:310-311. (Editorial).
47. Kuipers EJ., Nelis GF., KlinkenbergKnol EC., Snel P., Godfain D., Kolkman JJ.,
Festen HPM., Dent J., Zeitoun P., Havu N., Lamm M., Walan A.: Cure of
Helicobacter pylori infection in patients with reflux oesophagitis treated with long
term omeprazole reverses gastritis without exacerbation of reflux disease: results of a
randomized controlled trial. Gut 2004; 53/1:12-20.
48. McColl KEL.: Helicobacter pylori infection and long term proton pump inhibitor
therapy. Gut 2004; 53/1:5-7.
49. Sharma P.: Review article: Prevalence of Barrett’s oesophagus and metaplasia at the
gastro-oesophageal junction. Aliment. Pharm. Ther. 2004; 20/5.Suppl.:48-54.
50. Brandt MG., Darling GE., Miller L.: Symptoms, acid exposure and motility in
patients with Barrett’s esophagus. Canadian J.Surg. 2004; 47/1:47-51.
51. Lord RVN., Wickramsinghe K., Johansson JJ., DeMeester SR., Brabender J.,
DeMeester TR.: Cardiac mucosa in the remnant esophagus after esophagectomy in an
acquired epithelium with Barrett’s-like features. Surgery 2004; 136/3:633-640.
52. Peitz U., Vieth M., Pross M. Leodolter A., Malfertheiner P.: Cardia-type metaplasia
arising in the remnant esophagus after cardia resection. Gastrointest. Endoscopy
2004; 59/7:810-17.
53. Westhoff BC., Weston A., Cherian R., Sharma P.: Development of Barrett’s
esophagus six months after total gastrectomy. Am. J. Gastroenterol. 2004;
54. Weston AP., Sharma P., Mathur S., Banerjee S., Jafri AK., Cherian R., McGregor
D., Hassanein RS., Hall M.: Risk stratification of Barrett’s esophagus: Updated
prospective multivariate analysis. Am. J. Gastroenterol. 2004; 99/9:1657-66.
55. Gerson LB., Shetler K., Triadafilopoulos G.: Prevalence of Barrett’s esophagus in
asymptomatic individuals. Gastroenterology 2002; 123:461-467.
56. Dulai G., Jensen DM., Saad M. et al.: Simultaneous screening for Barrett’ and
colorectal cancer /Abstract/. Gastrointest. Endoscopy 2004; 59:AB259.
57. DeVault KR., Ward EM., Wolfsen HC. Et al.: Barrett’s esophagus (BE) is common
in older patients undergoing screening colonoscopy regardless of gastroesophageal
reflux (GER) symptoms. /Abstract/. Gastrointest. Endoscopy 2004; 59:AB111.
58. Siersema PD., Yu S., Sahbaie P. et al.: Colorectal neoplasia in veterans is
aspirin/NSAIDs /Abstract/. Gastrointest. Endosopy 2004; 59:AB259
59. Sarela Al., Verbeke CS., Pring C., Guillou PJ.: Is symptom control the correct end
point for proton pump inhibitor treatment in Barrett’s oesophagus? Gut 2004; 53/9:
1387-88. (letter).
60. Sharma P.: Low-grade dysplasia in Barrett’s esophagus. Gastroenterology 2004;
61. Shaheen NJ., Inadomi JM., Overholt BF., Sharma P.: What is the best management
strategy for high grade dysplasia in Barrett’s oesophagus? A cost effectiveness
analysis. Gut 2004;53/12:1736-44.
62. Giovannini M., Bories E., Pesenti C., Moutardier V., Monges G., Danisi C.,
Lelong B., Delpero JR.: Circumferential endoscopic mucosal resection in Barrett’s
esophagus with high-grade intraepithelial neoplasia or mucosal cancer. Preliminary
results in 21 patients. Endoscopy 2004; 36/9:782-87.
63. Meining A., Ott R., Becker I., Hahn S., Mühlen J., Werner M., Höfler H., Classen
M., Heldwein W., Rösch T.: The Munich Barrett follow up study: suspicion of
Barrett’s oesophagus based on either endoscopy or histology only – what is the
clinical significance? Gut 2004; 53/10:1402-07.
64. Sharma P., McQuaid, K., Dent J., Fennerty MB., Samplier R., Spechler S.,
Cameron A., Corley D., Falk G., Goldblum J., Hunter J., Jankowski J., Lundell
L., Reid B., Shaheen NJ., Sonnenberg A., Wang K., Weinstein W.: A critical review
of the diagnosis and management of Barrett’s esophagus: The AGA Chicago
workshop. Gastroenterology 2004; 127/1:310-330.
65. Spechler SJ.: What I do now to manage adenocarcinoma risk, and what I may be
doing in 10 years’ time. Aliment. Pharm. Ther. 2004; 20/5.Suppl. 105-110.
66. Crew KD., Neugut AI.: Epidemiology of upper gastrointestinal malignancies
Seminars of Oncology 2004; 31/4:450-464. (Review)
67. Solaymani-Dodoran M., Logan RFA, West J., Card T., Coupland C.: Risk for
oesophageal cancer in Barrett’s oesophagus and gastro-oesophageal reflux. Gut 2004;
68. vanBlankenstein M., Bohmer CJM, Hop WC.: The incidence of adenocarcinoma in
Barrett’s esophagus in an institutionalized population. Eur. J. Gastroenterol.-
Hepatol. 2004; 16/9:903-909.

69. Ye WM., Held M., Lagergren J., Engstrand L., Blot WJ., McLaughlin JK., Nyren
O.: Helicobacter pylori infection. J. National Cancer Inst. 2004; 96/5:388-96.
70. Brown A., Shaheen NJ.: Screening for upper gastrointestinal malignancies.
Seminars of Oncology 2004; 31/4:487-497. (Review)
71. Jankowski JA., Anderson M.: Management of oesophageal adenocarcinoma –
control of acid, bile and inflammation in intervention strategies for Barrett’s
oesophagus. Aliment. Pharm. Ther. 2004:20/5.Suppl.:71-80.
72. Reavis KM., Morris CD., Gopal DV., Hunter JG., Jobe BA.: Laryngopharyngeal
reflux symptoms better predict the presence of esophageal adenocarcinoma than
typical gastroesophageal reflux symptoms. Ann. Surg. 2004; 239/6:849-856.
73. Jaiswal K., Tello V., Lopez-Guzman C., Nwariaku F., Anthony T., Sarosi GA.:
Bile salt exposure causes phosphatidylinositol-3-kinase-mediated proliferation in a
Barrett’s adenocarcinoma cell line. Surgery 2004; 136/2:160-168.
74. Buskens CJ., Sivula A., vanRees BP., Haglund C., Offerhaus GJA., vanLanschot
JJB., Ristimaki A.: Comparison of cyclooxygenase 2 expression in adenocarcinomas
of the gastric cardia and distal oesophagus. Gut 2003; 52/12:1678-83.
75. Driessen A., Nafteaux P., Lerut T., VanRaemdonck D., DeLeyen P., Filez L.,
Penninckx F., Geboes K., Ectors N.: Identical cytokeratin expression pattern
CK7+/CK20- in esophageal and cardiac cancer: etiopathological and clinical
implications. Modern Pathology 2004; 17/1:49-55.
76. Rusch VW.: Are cancers of the esophagus, gastroesophageal junction, and cardia one
disease, two, or several? Seminars of Oncology 2004; 31/4:444-449. (Review)
77. Noel RJ., Putnam PE., Rothenberg ME.: Eosinophilic esophagitis. New Engl. J.
Med. (Letter) 2004; 351/9:940-41.
78. Potter JW. et al.: Eosiophilic esophagitis in adults.: An emerging problem with
unique esophageal features. Gastrointest. Endosc. 2004; 59:355-61.
79. Kaplan M., Mutlu EA., Jakate S., Bruninga K., Losurdo J., Losurdo J.,
Keshavarzian A.: Endoscopy in eosinophilic esophagitis: „Feline” esophagus and
perforation risk. Clin. Gastroenterol. Hepatol. 2003;1:433-37.
80. Ohlsson B., Ekberg O., Sundkvist G.: Achalasia: A vagal disease. Scand.J.
Gastroenterol. 2004; 39/6:527-30.
81. Eckardt VF., Gockel I., Bernhard G.: Pneumatic dilatation for achalasia: late results
of a prospective follow up investigation. Gut 2004; 53/5:629-33.
82. Hou MC. et al.: Antibiotic prophylaxis after endoscopic therapy prevents rebleeding
in acute variceal hemorrhage: A randomized trial. Hepatology 2004; 39:747-53.
83. Tripathi D., Lui HF., Helmy A., Dabos K., Forrest E., Stanley AJ., Jalan R.,
Redhead DN., Hayes PC.: Randomized controlled trial of long term portographic
follow up versus variceal band ligation following transjugular intrahepatic
portosystemic stent shunt for preventing oesophageal variceal rebleeding. Gut 2004;